Document Detail


Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide.
MedLine Citation:
PMID:  12756431     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The standard therapies of surgery, radiotherapy, and hormonal manipulations often fail to control metastatic prostate cancer (PC). Docetaxel and thalidomide may have activity in refractory PC. We highlight the potential pulmonary toxicity when docetaxel is combined with thalidomide. We reviewed three examples of docetaxel and thalidomide pulmonary toxicity at the National Cancer Institute (NCI) and summarized the published literature regarding docetaxel and thalidomide pulmonary toxicity. Docetaxel and thalidomide pulmonary toxicity has the following four main presentations: (1). symptomatic effusions; (2). dyspnea on exertion without any objective pathologic evidence; (3). interstitial lung disease; and (4). pulmonary embolus. As chemotherapy becomes more common in the treatment of PC, clinicians must consider possible pulmonary toxicities. If pulmonary symptoms or signs develop, clinicians should consider holding chemotherapy pending a complete evaluation.
Authors:
Robert J Behrens; James L Gulley; William L Dahut
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  American journal of therapeutics     Volume:  10     ISSN:  1075-2765     ISO Abbreviation:  Am J Ther     Publication Date:    2003 May-Jun
Date Detail:
Created Date:  2003-05-20     Completed Date:  2003-10-10     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  228-32     Citation Subset:  IM    
Affiliation:
Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA. behrensr@mail.nih.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiogenesis Inhibitors / adverse effects
Antineoplastic Agents, Phytogenic / adverse effects
Antineoplastic Combined Chemotherapy Protocols / administration & dosage,  adverse effects*
Dyspnea / chemically induced
Humans
Lung / drug effects*
Lung Diseases / chemically induced*
Lung Diseases, Interstitial / chemically induced
Male
Neoplasm Staging
Paclitaxel / adverse effects,  analogs & derivatives*
Pleural Effusion / chemically induced
Prostatic Neoplasms / drug therapy*,  pathology
Pulmonary Embolism / chemically induced
Risk Factors
Taxoids*
Thalidomide / adverse effects
Time Factors
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents, Phytogenic; 0/Taxoids; 15H5577CQD/docetaxel; 33069-62-4/Paclitaxel; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Severe methemoglobinemia after transesophageal echocardiography.
Next Document:  Outcome prediction in terms of functional disability and mortality at 1 year among ICU-admitted seve...